Enlivex Therapeutics is trading 10.3% up today at $2.15 as buyers return following a sharp dilution-driven drop tied to its recent $400 million crypto-linked private placement.
- The stock is staging a technical and sentiment-driven reversal after steep losses earlier this week triggered by the financing announcement and related market concerns.
- Today's gains come despite broader weakness across the biotechnology sector, suggesting a specific recovery from the recent overextended selloff.